Food and Wine Food and Wine

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA


Published on 2025-02-20 12:22:17 - manilatimes
  Print publication without navigation

  • YORVIPATH
  • (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval SINGAPORE,

The article from The Manila Times, published on February 21, 2025, discusses the approval of the first and only treatment for chronic hypoparathyroidism in Australia. This new treatment, named TRANSCON PTH (palopegteriparatide), has been developed by Ascendis Pharma A/S. Chronic hypoparathyroidism is a rare condition where the parathyroid glands do not produce enough parathyroid hormone, leading to low calcium levels in the blood. The approval by the Therapeutic Goods Administration (TGA) marks a significant advancement in managing this condition, offering patients a new therapeutic option to help normalize calcium levels and reduce the need for frequent calcium and vitamin D supplements. The treatment aims to improve the quality of life for those affected by providing a more physiological replacement of parathyroid hormone.

Read the Full manilatimes Article at:
[ https://www.manilatimes.net/2025/02/21/tmt-newswire/pr-newswire/first-and-only-treatment-for-chronic-hypoparathyroidism-approved-in-australia/2059832 ]